|
Adenocarcinoma of lung (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
EZH2 and the EMT markers E-cadherin and Vimentin were examined by IHC in lung adenocarcinoma specimens that were resected from 2003-2012.
|
31042721 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The response to SAHA was assessed at baseline and after alteration of EZH2 or HDAC mRNA expression in LUAD cell lines.
|
31456359 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
EZH2-expressing lung adenocarcinomas were shown to express the PD-L1 protein more frequently than were nonexpressing lesions.
|
30343006 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression and methylation data of lung adenocarcinoma were downloaded from TCGA database and categorized into EZH2 overexpression and EZH2 downregulation groups according to EZH2 expression.
|
30527357 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Knockdown of EZH2 could suppress the propagation and invasion of LUAD cells.
|
30280514 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
SPRY4-IT1 expression was observed to be significantly lower, while the expression of EZH2 was higher in the LA tissues than in the adjacent normal tissues.
|
28796375 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, our findings revealed the tumor suppressive function of Ezh2 in Kras-driven ADCs, underlining the importance of revaluating the application of EZH2 inhibitors in a variety of cancers.
|
28539837 |
2017 |
|
Adenocarcinoma of lung (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Long intergenic non-coding RNA 00152 promotes lung adenocarcinoma proliferation via interacting with EZH2 and repressing IL24 expression.
|
28109288 |
2017 |
|
Adenocarcinoma of lung (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
We further revealed that the 3 ceRNA triples (miR-21-5p-NKAPP1-PRDM11, miR-29c-3p-MSTO2P-EZH2 and miR-29c-3p-RPLP0P2-EZH2), whose high risk groups were associated with the poor prognosis of LUAD, may be considered as potential prognostic signatures.
|
28938616 |
2017 |
|
Adenocarcinoma of lung (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
SCC lesions have higher levels of the H3K27 methyltransferase EZH2 than the ADC lesions, but there is a clear lack of the essential Polycomb Repressive Complex 2 (PRC2) subunit EED in the SCC lesions.
|
28387316 |
2017 |
|
Adenocarcinoma of lung (disorder)
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In contrast to spontaneous lesions, carcinogen-induced Gprc5a<sup>-/-</sup> LUADs exhibited mutations (variants and copy number gains) in additional drivers (Atm, Kmt2d, Nf1, Trp53, Met, Ezh2).
|
28653505 |
2017 |
|
Adenocarcinoma of lung (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Zhang and colleagues have designed the open-source EZH2 inhibitor JQEZ5 and shown antitumor efficacy in vitro and in vivo in preclinical studies in murine and human lung adenocarcinoma models expressing high levels of EZH2.Cancer Discov; 6(9); 949-52.
|
27587466 |
2016 |
|
Adenocarcinoma of lung (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
As such, tumors feature a transcriptional program distinct from KRAS- and EGFR-mutant mouse lung cancers, but shared with human lung adenocarcinomas exhibiting high EZH2 expression.
|
27312177 |
2016 |
|
Adenocarcinoma of lung (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings define a new mechanism underlying EZH2 modulation by linking EZH2 acetylation to its phosphorylation that stabilizes EZH2 and promotes lung adenocarcinoma progression.
|
25800736 |
2015 |
|
Adenocarcinoma of lung (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, we demonstrated for the first time that the inhibition of EZH2 greatly increased the sensitivity of lung adenocarcinoma cells to the anti-VEGFR-2 drug AZD2171.
|
24850841 |
2014 |
|
Adenocarcinoma of lung (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
When EZH2 and TTF-1 expressions are considered together, they serve as a prognostic marker in patients with surgically resected lung adenocarcinomas.
|
24097870 |
2013 |
|
Adenocarcinoma of lung (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study suggests that EZH2 contributes to the progression of lung adenocarcinoma, and the deletion of EZH2 inhibits cancer and resensitizes cells to cisplatin in lung adenocarcinoma.
|
22552406 |
2012 |